Now We Can Look at Patients and Help Determine If They Need Treatment at All
Dr. Todd Cohen, former CEO of Carolina Urology Partners and Medical Director of Myriad Urology, brings you a casual, yet educational podcast about modern topics in Urology. Because every man with prostate cancer deserves a better answer.
In this episode Dr. Cohen sits down with Dr. Jonathan Henderson, CEO of Regional Urology in Shreveport Louisiana to discuss how the Prolaris test changed his treatment decision of multiple patients considering treatment or active surveillance. Dr. Henderson also talks about his reasoning for the early adoption of hereditary cancer screening and shares a compelling story about how genetic testing for BRCA status allowed him to get a compassionate writ for the PARP inhibitor – Lymparza which dramatically changed his patient's quality of life.
Listen to Dr. Jonathan Henderson, CEO of Regional Urology Shreveport Louisiana as he discusses his experience with being an early adopter of hereditary cancer screening in his practice. The role of the Prolaris test, and how it has helped change the treatment decisions for many patients considering active surveillance or definitive treatment is explored.
Dr. Henderson also shares a compelling patient story about how genetic testing for the BRCA gene and the use of Lynparza changed this patient’s quality of life and also his mindset on genetic testing.
“Even if each of us, each practicing Urologist gets to see that change once in his career… it’s an amazing result.”